Last update Nov. 20, 2020
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C19 H22 FN3 O3 is Grepafloxacin Hydrochloride in Molecular formula.
Is written in other languages:Main tradenames from several countries containing C19 H22 FN3 O3 in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 72 | % |
Molecular weight | 396 | daltons |
Protein Binding | 50 | % |
Tmax | 3 | hours |
T½ | 15.7 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It was withdrawn from the market around the world because its toxic effect on cardiovascular system (Sprandel 2003).
Due to the publication of reports of serious or potentially serious side effects in patients treated with fluoroquinolones, several health authorities propose restricting their indiscriminate outpatient use and reserving them for certain serious diseases (EMA 2018, FDA 2016).